Back to Journals » Drug Design, Development and Therapy » Volume 10

Spotlight on ixazomib: potential in the treatment of multiple myeloma

Authors Muz B, Ghazarian R, Ou M, Luderer M, Kusdono H, Azab AK

Received 28 October 2015

Accepted for publication 7 December 2015

Published 11 January 2016 Volume 2016:10 Pages 217—226

DOI https://doi.org/10.2147/DDDT.S93602

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Jingyi Li

Peer reviewer comments 4

Editor who approved publication: Prof. Dr. Wei Duan


Barbara Muz,1 Rachel Nicole Ghazarian,1,2 Monica Ou,1,3 Micah John Luderer,1 Hubert Daniel Kusdono,1,2 Abdel Kareem Azab1

1Department of Radiation Oncology, Cancer Biology Division, Washington University in St Louis School of Medicine, 2Department of Pharmaceutical and Administrative Sciences, St Louis College of Pharmacy, 3Department of Biology, St Louis University, St Louis, MO, USA

Abstract: Despite the significant therapeutic advances achieved with proteasome inhibitors (PIs) such as bortezomib and carfilzomib in prolonging the survival of patients with multiple myeloma, the development of drug resistance, peripheral neuropathy, and pharmacokinetic limitations continue to pose major challenges when using these compounds. Ixazomib is a second-generation PI with improved activity over other PIs. Unlike bortezomib and carfilzomib, which are administered by injection, ixazomib is the first oral PI approved by US Food and Drug Administration. This review discusses the biochemical properties, mechanisms of action, preclinical efficacy, and clinical trial results leading to the US Food and Drug Administration approval of ixazomib.

Keywords: proteasome inhibitor, oral administration, biological mechanism, clinical trials

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]